Canna Law Blog

AUGUST 25, 2020

MAPS anticipates good results, including FDA approval as early as 2022. The outfit actually began in response to the Drug Enforcement Administration (DEA) scheduling MDMA, more or less, which happened on an “emergency” basis in 1985 (you can view MAPS’ impressive archive and play-by-play on all of that here ). Just kidding!

DEA 85

DEA Therapy Decriminalization Pharmaceutical 85

Veriheal

JUNE 30, 2023

The document also addresses study participant safety emphasizing how psychedelics’ psychoactive effects increase the potential for abuse. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

APRIL 14, 2022

Similar issues arise under state and federal employee safety and worker Right-to-Know laws, as employees must be educated on the chemicals present and proper handling and risk management procedures. pursuant to Drug Enforcement Agency (DEA) or state-level programs).

Environment 52

Environment Agriculture Compliance Compliance 52

Veriheal

AUGUST 24, 2022

In a statement to The Denver Post, Natural Medicine Colorado—which sponsored the act—said “the measure is designed to prioritize mental health and healing, while balancing safety and access.” ” The spokesperson added, “Those are the sole motivations for the design of the initiative.

Legalization 108

Legalization Medicine Decriminalization Research and Development 108

Cannabis Law Report

AUGUST 23, 2021

Analysts predict that pet-and-animal product sales are among the fastest-growing sectors in the CBD market with estimated sales reaching $125 million by 2022. Unapproved animal drugs are considered to be ‘unsafe’ under the FDCA, because they have not been shown to meet FDA standards for safety and efficacy for their intended use.”

Pets 105

Pets Hemp CBD Food 105

Cannabis Law Report

APRIL 21, 2022

MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories. The safety and efficacy of MDMA-assisted therapy is currently under investigation. April 5, 2022.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

FEBRUARY 28, 2022

20 February 2022. Show More According to the Drug Enforcement Administration (DEA), Schedule I drugs have “no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.” Essay by I. Glenn Cohen & Mason Marks. war on drugs.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

AUGUST 6, 2021

Adjusted EBITDA loss in Q1 2022 was $64 million , a $29 million narrower loss versus Q1 2021 driven by higher sales and lower operating expenses. Adjusted EBITDA loss in Q1 2022 was negatively impacted by a $10.1 First Quarter Fiscal 2022 Financial Summary. (in Highlights. in millions of Canadian. dollars, unaudited).

Vaping 105

Vaping Research and Development Data Business 105

Project CBD

AUGUST 23, 2023

8 Safety Issues Associated with Synthetic Cannabinoids This new generation of designer drugs is reminiscent of “Spice,” “K2,” and other synthetic cannabinoids that emerged in the illicit drug market in the early 2000s. 9 We cannot assume that these novel compounds are safe based on the safety profile of natural cannabinoids. .”

Cannabinoids 141

Cannabinoids Hemp THC Safety 141

Cannabis Law Report

JUNE 1, 2021

Remains on track to achieve positive Adjusted EBITDA during the second half of FY 2022. opportunities in Fiscal 2022.” In Q1 2022, Canopy has expanded its portfolio of THC beverages with Tweed Iced Tea beverages (available in lemon and raspberry flavors, both with 5 mg THC) now shipping. state and federal law to U.S.

Data 95

Data Vaping Supply Chain Business 95

Cannabis Law Report

JULY 27, 2022

July 27, 2022. As of July 2022, 38 states have legalized the medical use of cannabis to differing degrees. For this reason, the FDA and DEA have concluded that marijuana has no federally approved medical use in the U.S. By Raymond Lahoud. How Does Federal Law Affect Immigration?

Marijuana 52

Marijuana DEA State Laws Policy 52

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Transaction expected to close in June 2022 , following anticipated shareholder approval. The offer price represents a premium of 51% to Novamind’s 20-day volume-weighted average price (“VWAP”) on the Canadian Securities Exchange (the “CSE”) as of April 8, 2022.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Sensi Seeds

NOVEMBER 28, 2018

Then, a blog post circulated online, notifying the industry that Spain’s food and safety authority, AECOSAN, had updated its legislation to prohibit the sale and distribution of products containing CBD being sold as food supplements. CBD market at a staggering $22 billion by 2022. Rumors, Statements and Raids ??

CBD 71

CBD Seed-To-Sale Food Research and Development 71

SpeedWeed

JULY 17, 2021

If passed, the bill would transfer most of the regulatory authority over cannabis from the Drug Enforcement Administration (DEA) to the Food and Drug Administration (FDA). The FDA would regulate the manufacture, marketing, and safety of cannabis products and packaging throughout the country.

Legalization 52

Legalization Collective Hash Legislation 52

Cannabis Law Report

JUNE 8, 2021

Currently Hemp Acres has 3000 acres under contract for 2021 production and anticipates contracting 10,000 acres in 2022. Requiring all delta-8 products to have a Drug Enforcement Administration (DEA) lab report by a third party testing company. Ordering all delta-8 products to undergo testing for residual solvents.

Hemp 102

Hemp Seed-To-Sale Food Research and Development 102

The Cannigma

MAY 15, 2023

Ketamine has a long safety record as an anesthetic since the 1980s, and it has also been successfully used “off-label” for over a decade to treat conditions such as anxiety, depression, OCD, and PTSD, among others. 2 How much does ketamine therapy cost?

Therapy 78

Therapy Access Blood Pressure Treatment 78

Cannabis Law Report

AUGUST 5, 2021

Schumer’s proposal (keep in mind that he is up for reelection in 2022) includes five key pillars: Federally deschedule cannabis- The Attorney General would have 60 days to formalize this and treat cannabis as a dietary supplement with the ability to make claims like other supplements. Key Elements of Proposal.

Banking 111

Banking Vaping Education DEA 111